In addition, the inherently high baseline genomic instability in BRCA2-mutant tumor lines may render them intrinsically hypersensitive to HU and cisplatin, limiting the extent of rescue achievable by siRNA-mediated A3B depletion alone. This evidence concerns the gene APOBEC3B and neoplasm.